Information Provided By: 
Fly News Breaks for March 12, 2018
SRPT
Mar 12, 2018 | 10:09 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $83 after the company announced its intention to file a new drug application on golodirsen by the end of 2018 to treat Duchenne muscular dystrophy boys with Exon 53 mutations. This could result in accelerated approval in 2019, two years ahead of expectations, Tenthoff tells investors in a research note. The analyst reiterates an Overweight rating on Sarepta. The stock in early trading is up 2% to $76.12.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
